The high cost of prescription drugs continues to burden patients and taxpayers. Surveys have shown that about three in ten adults do not take their medicines as prescribed because of the cost. Policymakers and regulators continue to explore various policies and enforcement actions to address the key drivers of high drug prices, address market distortions, and ensure patients and their families can access life-saving treatments. At the same time, challengers are actively pursuing several strategies, including litigation, that could frustrate state and federal measures that address prescription drug affordability.
ISSUE
Prescription Drug Affordability
Issue Metadata
Prescription Drug Affordability tracked topics
-
Price Gouging Laws
Cases Tracked: 6
-
Orange Book Patent Listings
Cases Tracked: 4
-
Product Specific Access Laws
Cases Tracked: 4
-
Prescription Drug Affordability Boards
Cases Tracked: 3
-
Transparency Laws
Cases Tracked: 2
Important Date
Scheduling Conference
Pretrial Conference
Status Hearing
Defendants' Response to Motion for Preliminary Injunction Due
Defendants' Response to Motion for Preliminary Injunction Due
Plaintiff's Response to Petition for Rehearing Due
Dive Deeper
O'Neill Institute
Recent Developments in Orange Book Litigation: How Patent Disputes Shape Prescription Drug AffordabilityO'Neill Institute
State Action to Lower Prescription Drug Prices: Navigating Patent PreemptionO'Neill Institute
A Setback for Prescription Drug Pricing: Eighth Circuit Rolls Back Minnesota Drug Price-Gouging LawO'Neill Institute
Pharmaceutical Industry Seeks to Thwart State Initiatives to Tackle Unaffordability of Prescription DrugsMore Issues
- 340B Program 15 cases
- Affordable Care Act 65 cases 6 Topics
- Anticompetitive Practices 19 cases
- Artificial Intelligence 3 cases
- Consumer Protections 11 cases
- Cost Containment 12 cases
- Equity 48 cases 1 Topics
- ERISA 15 cases
- Federal Health Funding 32 cases 4 Topics
- Health Information 2 cases
- Medicare Advantage 4 cases
- Medicare Drug Price Negotiation 20 cases
- No Surprises Act 34 cases 4 Topics
- Reproductive Health 41 cases 5 Topics
- Site-Neutral Payments 9 cases
- Transparency 5 cases